1,6-Hexanediamine, N-hydroxy- | 337905-45-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,6-Hexanediamine, N-hydroxy-
• 英文别名: N-(6-aminohexyl)hydroxylamine
• CAS: 337905-45-0
• 化学式: C₆H₁₆N₂O
• mdl: MFCD19207787
• 分子量: 132.2
• InChiKey: SFFWMTOKFWJWEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Primary N-hydroxylamines
  申请人：The Regents of the University of California

  公开号：US20030153535A1

  公开（公告）日：2003-08-14

  The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

  这项发明提供了含有主要N-羟胺及相关治疗、预防、诊断和筛选方法的药物组合物。这些药物组合物通常包括一种含有主要N-羟胺或其在药学上可接受的盐的口服可有效单位固体剂量的药物组合物，并且基本上不含与羟胺对应的亚硝基羟胺。
• PRIMARY N-HYDROXYLAMINES
  申请人：Ames Bruce N.

  公开号：US20080268537A1

  公开（公告）日：2008-10-30

  The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.
• ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20170247410A1

  公开（公告）日：2017-08-31

  A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.
• US6455589B1
  申请人：——

  公开号：US6455589B1

  公开（公告）日：2002-09-24
• [EN] PRIMARY N-HYDROXYLAMINES<br/>[FR] N-HYDROXYLAMINES PRIMAIRES
  申请人：UNIV CALIFORNIA

  公开号：WO2001030979A1

  公开（公告）日：2001-05-03

  The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.